Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions

Lignende værker

• Oncology Drugs Approved by the FDA in Early 2018
  Udgivet: (2018)
• FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma
  af: Bradford, Diana, et al.
  Udgivet: (2020)
• FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer
  af: Anscher, Mitchell S., et al.
  Udgivet: (2020)
• Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
  af: Raedler, Lisa A.
  Udgivet: (2015)
• Syntheses of FDA Approved HIV Protease Inhibitors
  af: Ghosh, Arun K., et al.
  Udgivet: (2001)